Yaghoob Farbood1, Masome Rashno2, Shahab Ghaderi3, Seyed Esmaeil Khoshnam1, Alireza Sarkaki1, Khodabakhsh Rashidi4, Mohammad Rashno5, Mohammad Badavi1. 1. Department of Physiology, Faculty of Medicine, Physiology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 2. Department of Physiology, Faculty of Medicine, Physiology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Electronic address: Masome.rashno@yahoo.com. 3. Department of Physiology, Faculty of Medicine, Physiology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Electronic address: Ghaderi.shahab@yahoo.com. 4. Research Center of Oils and Fats, Kermanshah University of Medical Sciences, Kermanshah, Iran. 5. Department of Immunology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Abstract
AIMS: Diabetes mellitus (DM), a chronic metabolic disease, is associated with behavioral deficits. It has been suggested that ellagic acid (EA), a natural polyphenol compound, has potent anti-diabetic, anti-inflammatory, and neuroprotective properties. The present study was aimed to explore the potential protective effects of EA against diabetes-associated behavioral deficits and verified possible involved mechanisms. MAIN METHODS: Fifty adult male Wistar rats were randomly divided into five groups: i.e., CON: normal rats treated with vehicle (5 ml/kg/day; P.O.), EA: normal rats treated with EA (50 mg/kg/day; P.O.), STZ: diabetic rats treated with vehicle (5 ml/kg/day; P.O.), STZ + INS: diabetic rats treated with insulin (6 IU/rat/day; S.C.), STZ + EA: diabetic rats treated with EA (50 mg/kg/day; P.O.). All the groups were under treatment for eight consecutive weeks. During the seventh and eighth weeks, behavioral functions of the rats were assessed by commonly used behavioral tests. Subsequently, pro- and anti-inflammatory cytokines, neurotrophic factors, and also histological changes were evaluated in both cerebral cortex and hippocampus of the rats. KEY FINDINGS: Chronic EA treatment attenuated anxiety/depression-like behaviors, improved exploratory/locomotor activities, and ameliorated cognitive deficits in diabetic rats. These results were accompanied by decreased blood glucose levels, modulation of inflammation status, improved neurotrophic support, and amelioration of neuronal loss in diabetic rats. In some aspects, treatment with EA was even more effective than insulin therapy. SIGNIFICANCE: The current work's data confirms that EA could potentially serve as a novel, promising, and accessible protective agent against diabetes-associated behavioral deficits, owing to its anti-hyperglycemic, anti-inflammatory, and neurotrophic properties.
AIMS: Diabetes mellitus (DM), a chronic metabolic disease, is associated with behavioral deficits. It has been suggested that ellagic acid (EA), a natural polyphenol compound, has potent anti-diabetic, anti-inflammatory, and neuroprotective properties. The present study was aimed to explore the potential protective effects of EA against diabetes-associated behavioral deficits and verified possible involved mechanisms. MAIN METHODS: Fifty adult male Wistar rats were randomly divided into five groups: i.e., CON: normal rats treated with vehicle (5 ml/kg/day; P.O.), EA: normal rats treated with EA (50 mg/kg/day; P.O.), STZ: diabeticrats treated with vehicle (5 ml/kg/day; P.O.), STZ + INS: diabeticrats treated with insulin (6 IU/rat/day; S.C.), STZ + EA: diabeticrats treated with EA (50 mg/kg/day; P.O.). All the groups were under treatment for eight consecutive weeks. During the seventh and eighth weeks, behavioral functions of the rats were assessed by commonly used behavioral tests. Subsequently, pro- and anti-inflammatory cytokines, neurotrophic factors, and also histological changes were evaluated in both cerebral cortex and hippocampus of the rats. KEY FINDINGS: Chronic EA treatment attenuated anxiety/depression-like behaviors, improved exploratory/locomotor activities, and ameliorated cognitive deficits in diabeticrats. These results were accompanied by decreased blood glucose levels, modulation of inflammation status, improved neurotrophic support, and amelioration of neuronal loss in diabeticrats. In some aspects, treatment with EA was even more effective than insulin therapy. SIGNIFICANCE: The current work's data confirms that EA could potentially serve as a novel, promising, and accessible protective agent against diabetes-associated behavioral deficits, owing to its anti-hyperglycemic, anti-inflammatory, and neurotrophic properties.
Authors: Jéssica Vanessa Dos Santos Lindoso; Salmon Rocha Alencar; Andressa Amorim Dos Santos; Renato Sampaio Mello Neto; Ana Victória da Silva Mendes; Mariely Mendes Furtado; Maisa Gomes da Silva; Ana Karolinne da Silva Brito; Emanuelle Karine Frota Batista; Silvia de Araújo França Baêta; Paulo Humberto Moreira Nunes; Massimo Lucarini; Alessandra Durazzo; Daniel Dias Rufino Arcanjo; Maria do Carmo de Carvalho E Martins Journal: Biology (Basel) Date: 2022-04-07
Authors: Jieping Yang; Yuanqiang Guo; Rupo Lee; Susanne M Henning; Jing Wang; Yajing Pan; Tianyu Qing; Mark Hsu; Alex Nguyen; Siddarth Prabha; Rashi Ojha; Gary W Small; David Heber; Zhaoping Li Journal: Curr Dev Nutr Date: 2020-11-25
Authors: Jozaa Z ALTamimi; Ghedeir M Alshammari; Nora A AlFaris; Reham I Alagal; Dalal H Aljabryn; Norah A Albekairi; Mahmoud Ahmad Alkhateeb; Mohammed Abdo Yahya Journal: Pharm Biol Date: 2022-12 Impact factor: 3.503